Company: APM
Filing Date: 2025-07-15
Form Type: DRS
Source: 0001213900-25-063899
Chunk: 247

Company: Aptorum Group Ltd
Filing Date: 2025-07-15
Form: DRS
Chunk 247
---
 |
| Investing activities                      |     |                     |   (1,278 | ) |     |      |        - |   |
| Financing activities                      |     |                     |  200,000 |   |     |      |  100,000 |   |
| Net decrease in cash and cash equivalents |     | $                   | (110,192 | ) |     | $    | (107,345 | ) |

Operating Activities

Net cash used in operating activities for the
year ended May 31, 2024 primarily resulted from grant related spending and an increase in spending to support fund raising and financial
statement preparation and audit.

In the years ended May 31, 2024 and 2023, DiamiR recognized $1,319,531
and $1,128,002 of grant revenue, respectively, offsetting research and development expenditures. As of May 31, 2024, DiamiR was eligible
to receive up to $0.5 million of additional funding under the CRP award through August 2025 to support qualified research and development
expenses under the grant, subject to availability of funds and satisfactory progress, as determined by the NIH. DiamiR expects net cash
used in operating activities to increase significantly in future periods as a result of unfunded research and development expenses.

<div align='center'>127</div>

Financing Activities

Net cash provided by
financing activities was $200,000 for the year ended May 31, 2024, representing proceeds from a founder loan. Net cash provided by
financing activities for the year ended May 31, 2023, was from proceeds received from issuing common stock to one of DiamiR’s
founders. There are no agreements with the founders with regard to any future financing.

Funding Requirements

DiamiR has not completed development of any of its product candidates.
DiamiR expects to continue to incur operating losses through at least fiscal 2026. Subject to receiving additional financing, it anticipates
that its expenses will increase substantially due to:

| ● | continued development of                                                                                                                                                                  
 CogniMIR®;                                                                                                                                                                                |
| ● | increased development activities for pipeline projects;                                                                                                                                   |
| ● | expanded laboratory facilities; and                                                                                                                                                       |
| ● | Additions to operational, financial and management information systems and personnel, including personnel to support DiamiR’s product development, and planned commercialization efforts. |

DiamiR expects that its existing
cash